



**ASX Announcement**  
**25 October 2021**

## **Receipt of R&D Tax Incentive Rebate**

Optiscan Imaging Limited (ASX: OIL) (**'the Company'** or **'Optiscan'**) is pleased to advise that the Company has received its R&D Tax Incentive rebate for the 2020/2021 financial year amounting to \$770,283. The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

The R&D receivable amount to 30 June 2021 accounted for in the Statement of Financial Position as at 30 June 2021 was \$847,324 and has been adjusted following final lodgement of the Company's income tax return to \$770,283.

- ends -

This announcement has been authorised for release by the Board of OIL.

**For investor queries, please contact:**

Darren Lurie  
Managing Director – Optiscan Imaging Limited  
E: [dlurie@optiscan.com](mailto:dlurie@optiscan.com)

**About Optiscan**

Optiscan is a global leader in the development of microscopic imaging and related technologies for surgery and medical research. Based in Victoria, Australia, Optiscan was established in 1994, and listed on the ASX in 1997 (ASX: OIL). Optiscan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level – instant "virtual biopsies" for cancer screening, diagnoses and in surgery.